Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: A population-based case-control and follow-up study

Breast Cancer Research

Volumn 8, Issue 6, 2006, Pages

  Einarsdóttir, Kristjana ^a   Rosenberg, Lena U ^a   Humphreys, Keith ^a   Bonnard, Carine ^b   Palmgren, Juni ^a,c   Li, Yuqing ^b   Li, Yi ^b   Chia, Kee S ^d   Liu, Edison T ^b   Hall, Per ^a   Liu, Jianjun ^b   Wedrén, Sara ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ATM PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHEK2 PROTEIN, HUMAN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; EXPLANATORY VARIABLE; FEMALE; FOLLOW UP; GENE DOSAGE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; POPULATION BASED CASE CONTROL STUDY; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; BREAST TUMOR; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; MUTATION; PROTO ONCOGENE; RISK; SURVIVAL;

AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHECKPOINT KINASE 2; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RISK; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 36749079314     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1623     Document Type: Article

References (85)

1. Thompson D Easton D The genetic epidemiology of breast cancer genes J Mammary Gland Biol Neoplasia 2004, 9:221-236. 10.1023/ B:JOMG.0000048770.90334.3b 15557796
2. Antoniou AC Pharoah PD McMullan G Day NE Stratton MR Peto J Ponder BJ Easton DF A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes Br J Cancer 2002, 86:76-83. 10.1038/ sj.bjc.6600008 11857015
3. Hunter K Welch DR Liu ET Genetic background is an important determinant of metastatic potential Nat Genet 2003, 34:23-24; 25. [author reply] 10.1038/ng0503-23b 12721549
4. Qiu TH Chandramouli GV Hunter KW Alkharouf NW Green JE Liu ET Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: Correlation to human disease Cancer Res 2004, 64:5973-5981. 10.1158/0008-5472.CAN-04-0242 15342376
5. Cozma D Lukes L Rouse J Qiu TH Liu ET Hunter KW A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers Genome Res 2002, 12:969-975. 1383737 12045150 10.1101/gr.210502
6. Matsuoka S Rotman G Ogawa A Shiloh Y Tamai K Elledge SJ Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro Proc Natl Acad Sci USA 2000, 97:10389-10394. 27034 10973490 10.1073/ pnas.190030497
7. Shieh SY Ahn J Tamai K Taya Y Prives C The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites Genes Dev 2000, 14:289-300. 316358 10673501
8. Zeng Y Forbes KC Wu Z Moreno S Piwnica-Worms H Enoch T Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1 Nature 1998, 395:507-510. 10.1038/26766 9774107
9. Lee JS Collins KM Brown AL Lee CH Chung JH hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response Nature 2000, 404:201-204. 10.1038/35004614 10724175
10. Savitsky K Bar-Shira A Gilad S Rotman G Ziv Y Vanagaite L Tagle DA Smith S Uziel T Sfez S A single ataxia telangiectasia gene with a product similar to PI-3 kinase Science 1995, 268:1749-1753. 10.1126/ science.7792600 7792600
11. Cortez D Wang Y Qin J Elledge SJ Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks Science 1999, 286:1162-1166. 10.1126/science.286.5442.1162 10550055
12. Khosravi R Maya R Gottlieb T Oren M Shiloh Y Shkedy D Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage Proc Natl Acad Sci USA 1999, 96:14973-14977. 24757 10611322 10.1073/pnas.96.26.14973
13. Olsen JH Hahnemann JM Borresen-Dale AL Brondum-Nielsen K Hammarstrom L Kleinerman R Kaariainen H Lonnqvist T Sankila R Seersholm N Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries J Natl Cancer Inst 2001, 93:121-127. 10.1093/jnci/93.2.121 11208881
14. Swift M Morrell D Massey RB Chase CL Incidence of cancer in 161 families affected by ataxia-telangiectasia N Engl J Med 1991, 325:1831-1836. 1961222
15. Thompson D Duedal S Kirner J McGuffog L Last J Reiman A Byrd P Taylor M Easton DF Cancer risks and mortality in heterozygous ATM mutation carriers J Natl Cancer Inst 2005, 97:813-822. 15928302
16. Inskip HM Kinlen LJ Taylor AM Woods CG Arlett CF Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia Br J Cancer 1999, 79:1304-1307. 10.1038/sj.bjc.6690209 10098776
17. Bell DW Varley JM Szydlo TE Kang DH Wahrer DC Shannon KE Lubratovich M Verselis SJ Isselbacher KJ Fraumeni JF Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome Science 1999, 286:2528-2531. 10.1126/ science.286.5449.2528 10617473
18. CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies Am J Hum Genet 2004, 74:1175-1182. 1182081 15122511 10.1086/421251
19. Meijers-Heijboer H van den Ouweland A Klijn J Wasielewski M de Snoo A Oldenburg R Hollestelle A Houben M Crepin E van Veghel-Plandsoen M Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations Nat Genet 2002, 31:55-59. 10.1038/ng879 11967536
20. Vahteristo P Bartkova J Eerola H Syrjakoski K Ojala S Kilpivaara O Tamminen A Kononen J Aittomaki K Heikkila P A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer Am J Hum Genet 2002, 71:432-438. 379177 12094328 10.1086/341943
21. Schechter AL Stern DF Vaidyanathan L Decker SJ Drebin JA Greene MI Weinberg RA The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 1984, 312:513-516. 10.1038/312513a0 6095109
22. King CR Kraus MH Aaronson SA Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 1985, 229:974-976. 10.1126/ science.2992089 2992089
23. Coussens L Yang-Feng TL Liao YC Chen E Gray A McGrath J Seeburg PH Libermann TA Schlessinger J Francke U Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 1985, 230:1132-1139. 10.1126/science.2999974 2999974
24. Bargmann CI Hung MC Weinberg RA The neu oncogene encodes an epidermal growth factor receptor-related protein Nature 1986, 319:226-230. 10.1038/ 319226a0 3945311
25. Akiyama T Sudo C Ogawara H Toyoshima K Yamamoto T The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity Science 1986, 232:1644-1646. 10.1126/science.3012781 3012781
26. Yarden Y Sliwkowski MX Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073 11252954
27. Threadgill DW Dlugosz AA Hansen LA Tennenbaum T Lichti U Yee D LaMantia C Mourton T Herrup K Harris RC Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype Science 1995, 269:230-234. 10.1126/science.7618084 7618084
28. Lee KF Simon H Chen H Bates B Hung MC Hauser C Requirement for neuregulin receptor erbB2 in neural and cardiac development Nature 1995, 378:394-398. 10.1038/378394a0 7477377
29. Revillion F Bonneterre J Peyrat JP ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 1998, 34:791-808. 10.1016/ S0959-8049(97)10157-5 9797688
30. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235:177-182. 10.1126/science.3798106 3798106
31. Slamon DJ Godolphin W Jones LA Holt JA Wong SG Keith DE Levin WJ Stuart SG Udove J Ullrich A Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989, 244:707-712. 10.1126/ science.2470152 2470152
32. Yu Q La Rose J Zhang H Takemura H Kohn KW Pommier Y UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1 Cancer Res 2002, 62:5743-5748. 12384533
33. Barlow C Eckhaus MA Schaffer AA Wynshaw-Boris A Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice Nat Genet 1999, 21:359-360. 10.1038/7684 10192382
34. Pietras RJ Poen JC Gallardo D Wongvipat PN Lee HJ Slamon DJ Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene Cancer Res 1999, 59:1347-1355. 10096569
35. Han W Kang D Lee JE Park IA Choi JY Lee KM Bae JY Kim S Shin ES Shin HJ A haplotype analysis of HER-2 gene polymorphisms: Association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea Clin Cancer Res 2005, 11:4775-4778. 10.1158/ 1078-0432.CCR-04-2208 16000574
36. Centre for Epidemiology Cancer Incidence in Sweden 2003: Official Statistics of Sweden Stockholm: The National Board of Health and Welfare 2005.
37. Magnusson C Baron JA Correia N Bergstrom R Adami HO Persson I Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy Int J Cancer 1999, 81:339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6 10209946
38. Magnusson C Colditz G Rosner B Bergstrom R Persson I Association of family history and other risk factors with breast cancer risk (Sweden) Cancer Causes Control 1998, 9:259-267. 10.1023/A:1008817018942 9684706
39. Magnusson CM Persson IR Baron JA Ekbom A Bergstrom R Adami HO The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years Int J Cancer 1999, 80:231-236. 10.1002/ (SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R 9935204
40. Moradi T Nyren O Zack M Magnusson C Persson I Adami HO Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden) Cancer Causes Control 2000, 11:523-531. 10.1023/A:1008900512471 10880034
41. Terry P Wolk A Persson I Magnusson C Brassica vegetables and breast cancer risk Jama 2001, 285:2975-2977. 10.1001/jama.285.23.2975 11410091
42. Isola J DeVries S Chu L Ghazvini S Waldman F Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples Am J Pathol 1994, 145:1301-1308. 7992835
43. Barrett JC Fry B Maller J Daly MJ Haploview: Analysis and visualization of LD and haplotype maps Bioinformatics 2005, 21:263-265. 10.1093/ bioinformatics/bth457 15297300
44. Qin ZS Niu T Liu JS Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms Am J Hum Genet 2002, 71:1242-1247. 385113 12452179 10.1086/344207
45. Stram DO Haiman CA Hirschhorn JN Altshuler D Kolonel LN Henderson BE Pike MC Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study Hum Hered 2003, 55:27-36. 10.1159/000071807 12890923
46. Gabriel SB Schaffner SF Nguyen H Moore JM Roy J Blumenstiel B Higgins J DeFelice M Lochner A Faggart M The structure of haplotype blocks in the human genome Science 2002, 296:2225-2229. 10.1126/science.1069424 12029063
47. Weale ME Depondt C Macdonald SJ Smith A Lai PS Shorvon SD Wood NW Goldstein DB Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: Implications for linkage-disequilibrium gene mapping Am J Hum Genet 2003, 73:551-565. 1180680 12900796 10.1086/378098
48. Iles MM Obtaining unbiased estimates of tagging SNP performance Ann Hum Genet 2006, 70:254-261. 10.1111/j.1529-8817.2005.00212.x 16626335
49. Nystrom L Larsson LG Rutqvist LE Lindgren A Lindqvist M Ryden S Andersson I Bjurstam N Fagerberg G Frisell J Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee Acta Oncol 1995, 34:145-152. 7718250
50. Brouillet JP Dujardin MA Chalbos D Rey JM Grenier J Lamy PJ Maudelonde T Pujol P Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer Int J Cancer 2001, 95:205-208. 10.1002/ 1097-0215(20010720)95:4<205::AID-IJC1035>3.0.CO;2-Y 11400111
51. Schaid DJ Rowland CM Tines DE Jacobson RM Poland GA Score tests for association between traits and haplotypes when linkage phase is ambiguous Am J Hum Genet 2002, 70:425-434. 384917 11791212 10.1086/338688
52. Chapman JM Cooper JD Todd JA Clayton DG Detecting disease associations due to linkage disequilibrium using haplotype tags: A class of tests and the determinants of statistical power Hum Hered 2003, 56:18-31. 10.1159/ 000073729 14614235
53. Gauderman WJ Sample size requirements for matched case-control studies of gene-environment interaction Stat Med 2002, 21:35-50. 10.1002/sim.973 11782049
54. Manolio TA Bailey-Wilson JE Collins FS Genes, environment and the value of prospective cohort studies Nat Rev Genet 2006, 7:812-820. 10.1038/ nrg1919 16983377
55. Hernan MA Hernandez-Diaz S Werler MM Mitchell AA Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology Am J Epidemiol 2002, 155:176-184. 10.1093/aje/155.2.176 11790682
56. Einarsdottir K Humphreys K Bonnard C Palmgren J Iles MM Sjolander A Li Y Chia KS Liu ET Hall P Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk PLoS Med 2006, 3:e168. 1457009 16671833 10.1371/journal.pmed.0030168
57. Nilsson Å Immigration and emigration in the postwar period Statistics Sweden: Demographic Reports 2004
58. Pritchard JK Przeworski M Linkage disequilibrium in humans: Models and data Am J Hum Genet 2001, 69:1-14. 1226024 11410837 10.1086/321275
59. Terwilliger JD Hiekkalinna T An utter refutation of the 'Fundamental Theorem of the HapMap' Eur J Hum Genet 2006, 14:426-437. 10.1038/ sj.ejhg.5201583 16479260
60. Goode EL Dunning AM Kuschel B Healey CS Day NE Ponder BA Easton DF Pharoah PP Effect of germ-line genetic variation on breast cancer survival in a population-based study Cancer Res 2002, 62:3052-3057. 12036913
61. Kilpivaara O Bartkova J Eerola H Syrjakoski K Vahteristo P Lukas J Blomqvist C Holli K Heikkila P Sauter G Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients Int J Cancer 2005, 113:575-580. 10.1002/ijc.20638 15472904
62. de Bock GH Schutte M Krol-Warmerdam EM Seynaeve C Blom J Brekelmans CT Meijers-Heijboer H van Asperen CJ Cornelisse CJ Devilee P Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant J Med Genet 2004, 41:731-735. 10.1136/ jmg.2004.019737 15466005
63. Kuschel B Auranen A Gregory CS Day NE Easton DF Ponder BA Dunning AM Pharoah PD Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk Cancer Epidemiol Biomarkers Prev 2003, 12:809-812. 12917215
64. Tamimi RM Hankinson SE Spiegelman D Kraft P Colditz GA Hunter DJ Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: A nested case-control study Breast Cancer Res 2004, 6:R416-422. 468661 15217510 10.1186/bcr809
65. Benusiglio PR Lesueur F Luccarini C Conroy DM Shah M Easton DF Day NE Dunning AM Pharoah PD Ponder BA Common ERBB2 polymorphisms and risk of breast cancer in a white British population: A case-control study Breast Cancer Res 2005, 7:R204-209. 1064135 15743501 10.1186/bcr982
66. Cox DG Hankinson SE Hunter DJ The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk Pharmacogenet Genomics 2005, 15:447-450. 15970791
67. Millikan RC Hummer AJ Wolff MS Hishida A Begg CB HER2 codon 655 polymorphism and breast cancer: Results from kin-cohort and case-control analyses Breast Cancer Res Treat 2005, 89:309-312. 10.1007/ s10549-004-2171-5 15754131
68. Koren M Kimmel G Ben-Asher E Gal I Papa MZ Beckmann JS Lancet D Shamir R Friedman E ATM haplotypes and breast cancer risk in Jewish high-risk women Br J Cancer 2006, 94:1537-1543. 10.1038/sj.bjc.6603062 16622469
69. Angele S Romestaing P Moullan N Vuillaume M Chapot B Friesen M Jongmans W Cox DG Pisani P Gerard JP ATM haplotypes and cellular response to DNA damage: Association with breast cancer risk and clinical radiosensitivity Cancer Res 2003, 63:8717-8725. 14695186
70. Lee KM Choi JY Park SK Chung HW Ahn B Yoo KY Han W Noh DY Ahn SH Kim H Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk Cancer Epidemiol Biomarkers Prev 2005, 14:821-825. 10.1158/ 1055-9965.EPI-04-0330 15824150
71. Bretsky P Haiman CA Gilad S Yahalom J Grossman A Paglin S Van Den Berg D Kolonel LN Skaliter R Henderson BE The relationship between twenty missense ATM variants and breast cancer risk: The Multiethnic Cohort Cancer Epidemiol Biomarkers Prev 2003, 12:733-738. 12917204
72. Dork T Bendix R Bremer M Rades D Klopper K Nicke M Skawran B Hector A Yamini P Steinmann D Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients Cancer Res 2001, 61:7608-7615. 11606401
73. Stredrick DL Garcia-Closas M Pineda MA Bhatti P Alexander BH Doody MM Lissowska J Peplonska B Brinton LA Chanock SJ The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer Hum Mutat 2006, 27:538-544. 10.1002/humu.20323 16652348
74. Scott SP Bendix R Chen P Clark R Dork T Lavin MF Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer Proc Natl Acad Sci USA 2002, 99:925-930. 117407 11805335 10.1073/pnas.012329699
75. Teraoka SN Malone KE Doody DR Suter NM Ostrander EA Daling JR Concannon P Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history Cancer 2001, 92:479-487. 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G 11505391
76. Sommer SS Jiang Z Feng J Buzin CH Zheng J Longmate J Jung M Moulds J Dritschilo A ATM missense mutations are frequent in patients with breast cancer Cancer Genet Cytogenet 2003, 145:115-120. 10.1016/ S0165-4608(03)00119-5 12935922
77. FitzGerald MG Bean JM Hegde SR Unsal H MacDonald DJ Harkin DP Finkelstein DM Isselbacher KJ Haber DA Heterozygous ATM mutations do not contribute to early onset of breast cancer Nat Genet 1997, 15:307-310. 10.1038/ng0397-307 9054948
78. Chen J Birkholtz GG Lindblom P Rubio C Lindblom A The role of ataxia-telangiectasia heterozygotes in familial breast cancer Cancer Res 1998, 58:1376-1379. 9537233
79. Concannon P ATM heterozygosity and cancer risk Nat Genet 2002, 32:89-90. 10.1038/ng0902-89 12205473
80. Renwick A Thompson D Seal S Kelly P Chagtai T Ahmed M North B Jayatilake H Barfoot R Spanova K ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles Nat Genet 2006, 38:873-875. 10.1038/ ng1837 16832357
81. Chenevix-Trench G Spurdle AB Gatei M Kelly H Marsh A Chen X Donn K Cummings M Nyholt D Jenkins MA Dominant negative ATM mutations in breast cancer families J Natl Cancer Inst 2002, 94:205-215. 11830610
82. Stankovic T Kidd AM Sutcliffe A McGuire GM Robinson P Weber P Bedenham T Bradwell AR Easton DF Lennox GG ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer Am J Hum Genet 1998, 62:334-345. 1376883 9463314 10.1086/301706
83. Larson GP Zhang G Ding S Foldenauer K Udar N Gatti RA Neuberg D Lunetta KL Ruckdeschel JC Longmate J An allelic variant at the ATM locus is implicated in breast cancer susceptibility Genet Test 1997, 1:165-170. 10464642
84. Szabo CI Schutte M Broeks A Houwing-Duistermaat JJ Thorstenson YR Durocher F Oldenburg RA Wasielewski M Odefrey F Thompson D Are ATM mutations 7271T->G and IVS10-6T->G really high-risk breast cancer-susceptibility alleles? Cancer Res 2004, 64:840-843. 10.1158/ 0008-5472.CAN-03-2678 14871810
85. Buchholz TA Weil MM Ashorn CL Strom EA Sigurdson A Bondy M Chakraborty R Cox JD McNeese MD Story MD A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls Cancer 2004, 100:1345-1351. 10.1002/cncr.20133 15042666